Cambridge, UK, 12th November 2024: Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created role of Chief Scientific & Innovation Officer.
Louise has almost 30 years’ experience working across the health and life sciences spectrum, working within academia, biotech and medium and large pharmaceutical organisations; from target discovery and R&D through to product launch and lifecycle management. Most recently Louise led the commercial…
Assembling the Technology-People-Money Trinity at the Genesis of Your SuccessWhilst different stakeholders may define value differently, translating the outcomes of leading-edge scientific research into value creation for all, including patients, investors, entrepreneurs, scientists, healthcare systems, and governments, requires excellence. Excellence in terms of the technology/product, people/team and investors/partners. Each year, Genesis is built to enable attendees to build their essential Life Science Trinity and why it is so valuable to attend.
Read more here
London, November 12, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with IMU Biosciences and is pleased to announce the placements of Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer. Founder and former Chief Executive Officer Dr. Adam Laing will assume the roles of President and Chief Scientific Officer.IMU Biosciences is a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine.Dr.…
Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.
Q3 2024 Take-Up Statistics
• Golden Triangle leasing activity totalled 84,400 sq ft in Q3 2024.
• Under-offer space totalled 262,700 sq ft at the close of Q3, indicating that activity will likely continue to rebound in Q4.
Evolving Demand and Supply
• Construction completions for the quarter totalled…
📖 Read November's eNews here ✅ Tony Jones, CEO, One Nucleus - Partnering, Policies and Parties✅ Genesis Conference App Now Open! Start Your Networking Here...✅ New Government Delivers Optimism and Concern for the Region’s Life Sciences by Tony Jones✅ CRISPR – A Twist in the Tale in the Ongoing Patent Battle in Europe, by Appleyard Lees IP LLP✅ European Rare Disease M&A Activity in 2024 Whitepaper from PharmaVentures✅ The Power of Belonging by Alicia Gailliez, One Nucleus✅ What Happened at ON Helix 2024? Read the Review✅ Visualising One Nucleus Members Around the World – A New…
Proteomics is a cutting-edge research area that examines proteins. These diverse and dynamic molecules are responsible for the execution of most biological processes and provide valuable indicators of human health and disease.
Read More Here
https://sourcebioscience.com/what-is-olink-proteomics/
Amsterdam, the Netherlands and Stevenage, UK – 4 November 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of Dr. Lara Boyd as Chief Business Officer.
Lara joins Tessellate BIO from F-star Therapeutics, an innovation focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics, where she held a number of senior roles, most recently VP Head of BD and Corporate Strategy, responsible for end-to-end business development activities. Prior to joining F-star…
• First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases
• NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target
• Inhibition of the mPTP in the brain prevents neuronal cell death and reduces neuroinflammation in animals
• $5M grant from The Michael J. Fox Foundation (MJFF) to advance NRG5051 into the clinic
• Grant will support CMC, GLP Toxicology,…
For researchers looking to optimize protocols for cell culture and differentiation of ES/iPS cells - AMSBIO has introduced the iMatrix Palette. This new kit containing all variants of their iMatrix recombinant laminin E8 fragment isoforms** saving researchers time, cost, and improving reproducibility.
Culturing human stem cells and iPS cells under feed-free conditions requires the use of ECM proteins as an anchor to promote adherence to laboratory plasticware. Unlike traditional laminin-based solutions, iMatrix E8 fragments are just…
London, October 28, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for ArcticZymes Technologies ASA (OSE: AZT) and is pleased to announce the placement of Dr. Frank Mathias as Chair of the Board.Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to…